Company Overview and News
Velpic Ltd (ASX:VPC) was active on all fronts in 2017, and there is early evidence in 2018 that the initiatives undertaken by the group are starting to pay dividends.
Velpic Ltd’s (ASX:VPC) completion of its rights issue shortfall is a positive development for the company as it builds its cash position to $3.2 million after costs.
Velpic Ltd’s (ASX:VPC) placement of 51 million shares and 14.5 million options is part of its $2.17 million rights issue mainly aimed at funding growth initiatives.
Velpic Ltd (ASX:VPC) has placed a further 44.2 million shares at $0.008 as part of its rights issue which has a maximum issue of 271 million shares valued at $2.17 million.
Velpic Ltd (ASX:VPC) has added another $822,000 to its cash balance following the completion of a rights priced at $0.008, with free attaching options on a 2 for 7 basis.
Velpic Ltd (ASX:VPC) has signed a memorandum of understanding with Bright Innovations, an Israeli technology company, to add its integrated solutions within Bright’s platform for smart cities.
Velpic Ltd’s (ASX:VPC) annualised committed monthly revenue (ACMR) is expected to exceed $800,000 by the end of December 2017, a 130% growth from the December 2016 quarter.
Velpic Ltd (ASX:VPC) is advancing the transformational partnership deal that it recently entered with Israeli-based security company NowForce Limited.
Chief Executive Officer Russell Francis tells Proactiveinvestors about Velpic's (ASX:VPC) recent deal with NowForce, a disruptive Israeli SaaS security software company. The partnership aims at bringing online learning to the global security sector and providing a value-added solution to new and existing clients of both platforms.
Velpic Ltd (ASX:VPC) is a technology company with two entities, being the cloud-based video eLearning platform Velpic, and the innovative branding, technology and digital marketing platform Dash Digital.
2018-04-25 - Asif
Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...
2018-04-25 - Asif
Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...
2018-04-23 - Asif
Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...